Sökning: WFRF:(Egan Allyson C.) >
The COVID-19 pandem...
-
Kronbichler, AndreasDepartment of Medicine, University of Cambridg, Cambridge, United Kingdom
(författare)
The COVID-19 pandemic and ANCA-associated vasculitis - reports from the EUVAS meeting and EUVAS education forum
- Artikel/kapitelEngelska2021
Förlag, utgivningsår, omfång ...
-
Elsevier,2021
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-185169
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-185169URI
-
https://doi.org/10.1016/j.autrev.2021.102986DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:149196016URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:for swepub-publicationtype
Anmärkningar
-
The Coronavirus Disease 2019 (COVID-19) pandemic influenced the management of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. A paucity of data exists on outcome of patients with vasculitis following COVID-19, but mortality is higher than in the general population and comparable to patients undergoing haemodialysis or kidney transplant recipients (reported mortality rates of 20-25%). Delays in diagnosis have been reported, which are associated with sequelae such as dialysis-dependency. Management of ANCA-associated vasculitis has not changed with the aim to suppress disease activity and reduce burden of disease. The use of rituximab, an important and widely used agent, is associated with a more severe hospital course of COVID-19 and absence of antibodies following severe acute respiratory syndrome (SARS)-CoV-2 infections, which prone patients to re-infection. Reports on vaccine antibody response are scarce at the moment, but preliminary findings point towards an impaired immune response, especially when patients receive rituximab as part of their treatment. Seropositivity was reported in less than 20% of patients when rituximab was administered within the prior six months, and the antibody response correlated with CD19+ B-cell repopulation. A delay in maintenance doses, if disease activity allows, has been suggested using a CD19+ B-cell guided strategy. Other immunosuppressive measures, which are used in ANCA-associated vasculitis, also impair humoral and cellular vaccine responses. Regular measurements of vaccine response or a healthcare-policy time-based strategy are indicated to provide additional doses ("booster") of COVID-19 vaccines. This review summarizes a recent educational forum and a recent virtual meeting of the European Vasculitis Society (EUVAS) focusing on COVID-19.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Geetha, DuvuruDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
(författare)
-
Smith, Rona MDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom
(författare)
-
Egan, Allyson C.Department of Medicine, University of Cambridge, Cambridge, United Kingdom
(författare)
-
Bajema, Ingeborg M.Department of Pathology, L1Q, Leiden University Medical Center, Leiden, the Netherlands
(författare)
-
Schönermarck, UlfDivision of Nephrology, Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany
(författare)
-
Mahr, AlfredDepartment of Rheumatology, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland
(författare)
-
Anders, Hans-JoachimDivision of Nephrology, Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany
(författare)
-
Bruchfeld, AnnetteKarolinska Institutet,Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Njurmedicinska kliniken US,CLINTEC Karolinska Institutet, Stockholm, Sweden(Swepub:liu)anbru14
(författare)
-
Cid, Maria C.Department of Autoimmune Diseases, Hospital Clinic, University of Barcelona, Institut dInvestigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
(författare)
-
Jayne, David R. W.Department of Medicine, University of Cambridge, United Kingdom
(författare)
-
Department of Medicine, University of Cambridg, Cambridge, United KingdomDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Autoimmunity Reviews: Elsevier20:121568-99721873-0183
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Kronbichler, And ...
-
Geetha, Duvuru
-
Smith, Rona M
-
Egan, Allyson C.
-
Bajema, Ingeborg ...
-
Schönermarck, Ul ...
-
visa fler...
-
Mahr, Alfred
-
Anders, Hans-Joa ...
-
Bruchfeld, Annet ...
-
Cid, Maria C.
-
Jayne, David R. ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
- Artiklar i publikationen
-
Autoimmunity Rev ...
- Av lärosätet
-
Linköpings universitet
-
Karolinska Institutet